Dr. Philip Gould FRSC, SRPharmS, C. Chem

152 High Street North, Stewkley, Leighton Buzzard, Bedfordshire LU7 0EP, United Kingdom

Phone: +44 (0)7718 794679 **Mobile (cell)** : +44(0)7802 636998
E-mail: phil@jadarapharma.com

Profile

Phil Gould is a senior pharmaceutical technical professional with extensive international 'blue chip' industry experience of drug discovery and development. He has a background in pharmaceutical development, pharmaceutical technology, formulations design and solid-state pharmaceutics (salts, hydrates, polymorphs, pseudopolymorphs, co-crystals etc.), based on an in depth understanding of physical chemistry, pharmaceutics, bio-pharmaceutics and drug design.

Phil was educated with an honours degree in chemistry, a PhD in physical chemistry, and is a Chartered Chemist, a Fellow of the Royal Society of Chemistry, a Scientist of the Royal Pharmaceutical Society and honorary Professor of Pharmaceutical Sciences.

Phil has published over 30 peer-reviewed papers in pharmaceutics and pharmaceutical technology, given over 40 seminars in the areas of pharmaceutical sciences, pharmaceutical technology, R&D strategy and R&D management. He has also published a book chapter in solid dosage form technology, and been an inventor on 4 pharmaceutical patents. Phil has been, and continues to be, a manuscript reviewer for major pharmaceutical scientific journals.

Personal Information

Marital status: Married Nationality: British Place of Birth: London

Education

BSc. Chemistry (Hons), University of Hull, 1975. Awarded J.J. Kipling Prize Physical Chemistry.

Ph.D. Physical Chemistry, University of Hull, 1979.

Business Systems: Institute of Management Development, Geneva, 1993.

Honorary Professor of Industrial Pharmacy, Liverpool John Moores University.

Employment Experience

Current

2005 - to date, Founder and CEO, Jadara Pharma Ltd – A healthcare technical & business consultancy with international contracts in technical expert reports (drug discovery, pharmaceutical solid-state, pharmaceutics, formulation and technology), non-executive services, strategic business planning, fund raising, patent litigation, strategic product development, product commercialisation, spin out portfolio management and investor support to trade sale or IPO.

Global clients in pharma (blue chip and SMEs), biotech, medical diagnostics and medical devices as well as venture capital due diligence. See *www.jadarapharma.com*.

Previous Experience

2010 - 2014, Director - RedX Pharma Ltd – a venture backed drug discovery company focused in the areas of infection, oncology and cardiovascular medicine. Role as pharmaceutical development advisor and Chair/Co-ordinator of the Scientific Advisory Board for Anti-infective and Oncology Divisions.

2007 - 2010, Director - Bradford Pharma Ltd – a venture capital backed Avecia (AZ) spin out company, based in the UK and focused on redox API process chemistry. Sold to RedX Pharma Ltd.

2006 - 2012, Chief Business Officer - Liverpool School of Tropical Medicine – internal drug discovery and product development consultant, R&D collaborations for fund raising for neglected disease drug discovery programmes with benefactor foundations, spin out of several businesses.

2003 - 2010, Director - Lectus Therapeutics Ltd - a Cambridge based small molecule drug discovery, company focused on ion channels to treat neuropathic pain and was a spin out from Bristol University. Sold to UCB Pharma. Discovery/development strategic advisor for programmes.

1999 - 2000, Director - **OraTol Ltd.** - an oral tolerance allergy company backed by two major venture capital groups (Atlas and Nomura).

Previous Employment History

1999 - 2005 **Chief Executive, Provalis plc** – a dynamic diversified, LSE & NASDAQ listed, pharmaceutical and medical diagnostics company with R&D base in drug delivery & formulation (peptides), vaccines (respiratory) & diagnostics. Group sold to Galen (Pharmaceuticals) and BioRad (Diagnostics).

1998 - 1999 **Group R&D Director, Cortecs plc** – Biotechnology Company with wide interests in vaccines, drug delivery (peptides) and diagnostics. Directed research programmes.

1988 - 1997 **Head, New Product Introduction and Product Technology, GlaxoWellcome Group (Now GlaxoSmithKline).** Responsible for final stages of product development, technology transfer and product start up across a wide range of product technologies; solid dosage forms, steriles and parenterals and respiratory products and devices. Responsible for a wide range of product, process and packaging technologies.

1985 - 1988 **Senior Manager Pharmaceutical Development Group: Lederle Laboratories (now Wyeth/Pfizer)** developing a wide range of pharmaceutical products for global markets from novel NCE's and established API's. NCE pharmaceutics, 'development candidate' selection and development of sterile, solid, semi-solid and lyophilised products.

1980 - 1985 **Principal Research Scientist: Pharmaceutical Development: Pfizer Central Research –** API form selection, pre-formulation, formulations research, pharmaceutical technology. The development of a wide range of dosage forms; solid dosage, sterile liquids, lyophiles and also specific controlled release animal health products.

1978 - 1980 **Section Leader Drug Design: Reckitt & Colman Pharmaceutical Division –** physicochemical profiling and lead selection of a number of NCE candidates linking to ADME profiling and formulations research.

Professional Memberships

Fellow of the Royal Society of Chemistry & RSC Chartered Chemist, 1980 –

Charter Member of American Society of Pharmaceutical Scientists, 1986 - 2020

Institute for Management Development (IMD) Alumni, 1994 –

Member of the Institute of Directors, 2000 – 2016.

Scientific Member Royal Pharmaceutical Society, 2014 -

Advisory Boards

Member of IUPAC Sub-Committee on the Use of Salt Forms in Drug Development; 1995 - 1998.

Member of GlaxoWellcome Drug Development Management Committee; 1992 -1997.

Chairmanship of GlaxoWellcome API and Product Technical Review Committee (Respiratory & Solid Dosage Form Products); 1995 -1997

Member of Provalis Vaccine Development Advisory Board; 2000-2002.

Member of Lectus Therapeutics Scientific Advisory Board on ion channels and accessory proteins for pain therapeutics; 2003 – 2008.

Chairmanship of Anti-infectives and Oncology Scientific Advisory Boards, RedX Pharma Ltd; 2010 – 2013.

Assessor for UK Technology Strategy Board – Driving Innovation (Infectious Disease Diagnostics); 2010/11.

Member of ESAC for Filariasis R&D Programme, AWOL/LSTM and Bill & Melinda Gates Foundation Programme, 2009 – 2013.

Assessor for UK Funding Programme in Life Sciences – National Biocatalyst Fund, Infection and vaccines; 2012.

Assessor for UK Biocatalyst Fund and MediTech Fund – Peer Reviews of science, technology and investment potential; 2012 - to date.

Biochemical Industries Association – Biotech Business mentor; 2004 - 2009.

BioNow Life Science Mentor; 2013 – 2016

Steering Committee Member – Pharmaceutical Investments, LSBC, Warsaw, Poland; 2015 – 2016

Pharmaceutical assessor; Innovate UK and UK Newton Fund 2016 – to date.

Precision Medicine Investment assessor, Innovate UK 2018 -

Publications, Seminars, Books, Patents

A series of scientific papers have been published, and seminars given in the areas of pharmaceutics, formulation research, drug salt form selection, solid state hydrates, the use of co-solvents, pharmaceutical technology, respiratory product design, tablet formulation, controlled release dosage forms, formulation optimisation and technology transfer.

Phil continues to give seminars in the areas of physical pharmacy and formulation, and on the business mechanics of drug development. He has also been a manuscript reviewer for the American Chemical Society and for the journals: 'Journal of Pharmaceutical Sciences', 'Drug Development and Industrial Pharmacy' and 'Crystal Growth and Design'.

Pharmaceutical Expert

Phil has been a pharmaceutical expert on a number of patent litigation disputes that have related to pharmaceutical salt forms, pharmaceutical formulation, pharmaceutical pro-drugs and a wide variety of pharmaceutical technology. He has dealt with a number of cases for both innovator and generic companies in the USA and EU, and has made declarations on behalf of companies with regulatory authorities. He has been deposed for evidence a number of times (>20).

Patent Litigation, Depositions and Testimony in the Last Four Years

No depositions or trial testimony have been given in the last four years; (May 2017- May 2021).